OSMT
Income statement / Annual
Last year (2020), RVL Pharmaceuticals plc's total revenue was $177.88 M,
a decrease of 25.89% from the previous year.
In 2020, RVL Pharmaceuticals plc's net income was -$79.59 M.
See RVL Pharmaceuticals plc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$177.88 M |
$240.03 M |
$263.70 M |
$245.75 M |
$218.46 M |
| Cost of Revenue |
$74.48 M
|
$111.63 M
|
$135.01 M
|
$125.19 M
|
$125.62 M
|
| Gross Profit |
$103.40 M
|
$128.40 M
|
$128.69 M
|
$120.56 M
|
$92.84 M
|
| Gross Profit Ratio |
0.58
|
0.53
|
0.49
|
0.49
|
0.42
|
| Research and Development Expenses |
$19.70 M
|
$32.32 M
|
$48.76 M
|
$42.69 M
|
$29.06 M
|
| General & Administrative Expenses |
$81.96 M
|
$93.03 M
|
$74.24 M
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$81.96 M
|
$93.03 M
|
$74.24 M
|
$0.00
|
$0.00
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$56.95 M
|
$65.96 M
|
| Operating Expenses |
$101.66 M
|
$125.35 M
|
$123.00 M
|
$99.64 M
|
$95.02 M
|
| Cost And Expenses |
$176.14 M
|
$236.98 M
|
$258.02 M
|
$224.83 M
|
$220.64 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$14.40 M
|
$18.21 M
|
$20.79 M
|
$29.05 M
|
$20.19 M
|
| Depreciation & Amortization |
$21.03 M
|
$57.02 M
|
$81.57 M
|
$46.45 M
|
$23.59 M
|
| EBITDA |
-$48.86 M |
-$50.68 M |
-$664.39 M |
-$10.14 M |
-$8.29 M |
| EBITDA Ratio |
-0.27
|
-0.21
|
-2.52
|
-0.04
|
-0.04
|
| Operating Income Ratio |
0.01
|
0.01
|
0.02
|
0.09
|
-0.01
|
| Total Other Income/Expenses Net |
-$86.03 M
|
-$301.07 M
|
$545.73 M
|
-$106.56 M
|
-$49.89 M
|
| Income Before Tax |
-$84.29 M
|
-$298.02 M
|
-$118.66 M
|
-$85.64 M
|
-$52.07 M
|
| Income Before Tax Ratio |
-0.47
|
-1.24
|
-0.45
|
-0.35
|
-0.24
|
| Income Tax Expense |
-$4.70 M
|
-$27.12 M
|
-$9.27 M
|
-$40.49 M
|
-$10.25 M
|
| Net Income |
-$79.59 M
|
-$270.90 M
|
-$109.40 M
|
-$45.15 M
|
-$41.82 M
|
| Net Income Ratio |
-0.45
|
-1.13
|
-0.41
|
-0.18
|
-0.19
|
| EPS |
-1.27 |
-5.17 |
-2.42 |
-1.05 |
-0.98 |
| EPS Diluted |
-1.27 |
-5.17 |
-2.42 |
-1.05 |
-0.98 |
| Weighted Average Shares Out |
$62.79 M
|
$52.37 M
|
$45.28 M
|
$42.85 M
|
$42.85 M
|
| Weighted Average Shares Out Diluted |
$62.79 M
|
$52.37 M
|
$45.28 M
|
$42.85 M
|
$42.85 M
|
| Link |
|
|
|
|
|
